Uncategorised - European Medical Journal

Continue
2 Mins
12th November 2019

The Mutational Signature of Spontaneously Developing Tumours in MLH1-/- Mice - Potential Consequences for Immunotherapeutic Approaches

Mismatch repair-deficient (MMR-D) tumours exemplify the prototypic hypermutator phenotype. Owing to the high mutation rates, many neo-antigens…
3 Mins
12th November 2019

Epithelial Myoepithelial Carcinoma of the Hard Palate: A Case Report with a Review of the Literature

Epithelial myoepithelial carcinoma (EMC) was initially described by Donath et al…
1 Mins
12th November 2019

The 2016-2019 ImmunoTOX Assessment Board Report: Results from a Descriptive Real-Life Study of a Collaborative Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors

Although immunotherapy is better tolerated globally than chemotherapy, immune checkpoint inhibitors may be associated with immune-related…
8 Mins
12th November 2019

PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer

Physiologically, cells are equipped with DNA damage repair systems that can correct various errors…
3 Mins
12th November 2019

Branchial Cleft Cyst – A Misdiagnosed Developmental Anomaly

The branchial cleft’s embryological journey begins between the first 3–8 weeks of intrauterine life. Five mesodermal arches form by the inpouching…
2 Mins
12th November 2019

Measuring the Cancer Burden in Europe: the European Cancer Information System (ECIS)

Cancer is the second leading cause of mortality in European Union (EU) Member States,1 with more than 1.4 million deaths…
1 Mins
12th November 2019

Phase I Combination Dose-Finding and Phase II Expansion Cohorts of Lenvatinib with Etoposide and Ifosfamide in Patients Aged 2 to ≤25 Years with Relapsed or Refractory Osteosarcoma

Osteosarcoma is the most common primary bone tumour in adolescents and young adults, with no survival improvement in the last few decades…
9 Mins
12th November 2019

Discovery of a ‘Grail-Shaped’ Drug: Ne-ratinib and the Downregulation of Mutant RAS

The drug neratinib (HKI-272, Nerlynx®) was originally developed by Wyeth Research Laboratories, with its initial characterisation published in 2004…
11 Mins
12th November 2019

Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer

In the era of target and immunotherapy, the multidisciplinary approach of lung cancer is now mandatory. Close collaboration between pulmonologists…
7 Mins
12th November 2019

Follow-Up of Accessory Breast Cancer Patient: Case Report

Accessory breast is a congenital atavism condition. Accessory breast tissue may arise anywhere along the mammary line because of the failure of complete…